Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair

Molecular Pharmacology

Volumn 50, Issue 6, 1996, Pages 1472-1478

  Fujimori, Akira ^a,b   Gupta, Malini ^a   Hoki, Yuko ^a,b   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CHLORAMPHENICOL ACETYLTRANSFERASE; CISPLATIN; DNA TOPOISOMERASE; ETOPOSIDE; MESYLIC ACID METHYL ESTER; OLIGONUCLEOTIDE;

ARTICLE; BREAST CANCER; CELL CYCLE PHASE; CELL STRAIN HL 60; CLONOGENESIS; CONTROLLED STUDY; CROSS RESISTANCE; DNA CLEAVAGE; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DNA INTERACTION; TUMOR GROWTH; ULTRAVIOLET RADIATION;

BREAST NEOPLASMS; CAMPTOTHECIN; CELL CYCLE; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; HUMANS; METHYL METHANESULFONATE; MUTAGENESIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030476665     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Champoux, J. Mechanistic aspects of type-I topoisomerases, in DNA Topology and its Biological Effects (J. C. Wang and N. R. Cozarelli, eds.). Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 217-242 (1990).
2. Gupta, M., A. Fujimori, and Y. Pommier. Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta 1262:1-14 (1995).
3. Pommier, Y., and A. Tanizawa. Camptothecins: mechanism of action and resistance. Cancer Invest. 11:3-6 (1994).
4. Chen, A. Y., and L. F. Liu. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 94:194-218 (1994).
5. Slichenmyer, W. J., E. K. Rowinsky, R. C. Donehower, and S. H. Kaufmann. The current status of camptothecin analogs as anticancer agents. J. Natl. Cancer Inst. 85:271-287 (1993).
6. Potmesil, M. Camptothecins: from bench research to hospital wards. Cancer Res. 54:1431-1439 (1994).
7. Pommier, Y., F. Leteurtre, M. R. Fesen, A. Fujimori, R. Bertrand, E. Solary, G. Kohlhagen, and K. W. Kohn. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12: 530-542 (1994).
8. Goldwasser, F., T. Shimizu, J. Jackman, Y. Hoki, P. M. O'Connor, K. W. Kohn, and Y. Pommier. Correlations between S- and G2-phase arrest and cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 56:4430-4437 (1996).
9. Goldwasser, F., I. Bae, M. Valenti, K. Torres, and Y. Pommier. Topoisomerase I-related parameters, and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res. 55:2116-2121 (1995).
10. Kauh, E. A., and M.-A. Bjornsti. SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I. Proc. Natl. Acad. Sci. USA 92:6299-6303 (1995).
11. Fujimori, A., W. G. Harker, G. Kohlhagen, Y. Hoki, and Y. Pommier. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell resistant to camptothecin. Cancer Res. 55:1339-1346 (1995).
12. Pommier, Y., G. Kohlhagen, F. Kohn, F. Leteurtre, M. C. Wani, and M. E. Wall. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc. Natl. Acad. Sci. USA 92:8861-8865 (1995).
13. Kohn, K. W., R. A. G. Ewig, L. C. Erickson, and L. A. Zwelling. Measurement of strand breaks and crosslinks by alkaline elution, in DNA Repair: A Laboratory Manual of Research Procedures (E. C. Friedberg and P. C. Hanawalt, eds.). Marcel Dekker Inc., New York, NY, 379-401 (1981).
14. Bertrand, R., and Y. Pommier. Assessment of DNA damage in mammalian cells by DNA filtration methods, in Cell Growth and Apoptosis: A Practical Approach (G. Studzinski, ed.). IRL Press, Oxford. 96-117 (1995).
15. Covey, J. M., C. Jaxel, K. W. Kohn, and Y. Pommier. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 49:5016-5022 (1989).
16. An, G., K. Hidaka, and L. Siminovitch. Expression of bacterial b-galactosidase in animal cells. Mol. Cell. Biol. 2:1628-1632 (1982).
17. Fujimori, A., W. G. Harker, G. Kohlhagen, Y. Hoki, and Y. Pommier. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55:1339-1346 (1995).
18. Pommier, Y., J. Jenkins, G. Kohlhagen, and F. Leteurtre. DNA recombinase activity of eukaryotic DNA topoisomerase I: effects of camptothecin and other inhibitors. Mutat. Res. 337:135-145 (1995).
19. Nelson, W. G., and M. B. Kastan. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14:1815-1823 (1994).
20. Smith, M., I. -T. Chen, Q. Zhan, P. O'Connor, and A. Fornace, Jr. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10:1053-1059 (1995).
21. Jaxel, C., G. Capranico, D. Kerrigan, K. W. Kohn, and Y. Pommier. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem. 266:20418-20423 (1991).
22. Svejstrup, J. Q., K. Christiansen, I. I. Gromova, A. H. Andersen, and O. Westergaard. New technique for uncoupling the cleavage and relegation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site. J. Mol. Biol. 222:669-678 (1991).
23. Bjornsti, M. -A., P. Benedetti, G. A. Viglianti, and J. C. Wang. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res. 49:6318-6323 (1989).
24. Fujimori, A., Y. Hoki, N. Popescu, and Y. Pommier. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. Oncol. Res. 8: in press (1996).
25. Tamura, H. -O., C. Kohchi, R. Yamada, T. Ikeda, O. Koiwai, E. Patterson, J. D. Keene, K. Okada, E. Kjeldsen, K. Nishikawa, and T. Andoh. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res. 19:69-75 (1991).
26. Kubota, N., F. Kanzawa, K. Nishio, Y. Takeda, T. Ohmori, Y. Fujiwara, Y. Terashima, and N. Saijo. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun. 188:571-577 (1992).
27. Knab, A. M., J. Fertala, and M. -A. Bjornsti. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. J. Biol. Chem. 268: 22322-22330 (1993).
28. Levin, N. A., M. -A. Bjornsti, and G. R. Fink. A novel mutation in DNA topoisomerase I of yeast causes DNA damage and RAD9-dependent cell cycle arrest. Genetics 133:799-814 (1993).
29. Tanizawa, A., and Y. Pommier. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res. 52:1848-1854 (1992).
30. Rubin, E., P. Pantazis, A. Bharti, D. Toppmeyer, B. Giovanella, and D. Kufe. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J. Biol. Chem. 269: 2433-2439 (1994).
31. Benedetti, P., P. Fiorani, L. Capuani, and J. C. Wang. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res. 53:4343-4348 (1993).
32. Goldwasser, F., I. S. Bae, K. Torres, and Y. Pommier. Topoisomerase I-related parameters and camptothecin activity in the colon cell lines from the National Cancer Institute anticancer screen. Cancer Res. 55:2116-2121 (1995).
33. Beidler, D. R., and Y. -C. Cheng. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol. 47:907-914 (1995).
34. Lanza, A., S. Tornaletti, M. Stefanini, H. H. Evans, M. Ricanati, G. C. B. Astaldi Ricotti, and A. M. Pedrini. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases. Carcinogenesis 14:1759-1763 (1993).
35. Hsiang, Y. -H., M. G. Lihou, and L. F. Liu. Arrest of DNA replication by drug-stabilized topoisomerase 1-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077-5082 (1989).
36. Holm, C., J. M. Covey, D. Kerrigan, and Y. Pommier. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49:6365-6368 (1989).
37. Shin, C. -G., and R. M. Snapka. Exposure to camptothecin breaks leading and lagging strand simian virus 40 DNA replication forks. Biochem. Biophys. Res. Commun. 168:135-140 (1990).
38. Tsao, Y. P., A. Russo, G. Nyamusa, R. Silber, and L. F. Liu. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res. 53:5908-5914 (1993).
39. Ryan, A. J., S. Squires, H. L. Strutt, and R. T. Johnson. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res. 19:3295-3300 (1991).
40. Squires, S., A. Ryan, H. Strutt, and R. Johnson. Hypersensitivity of Cockayne's syndrome cells to camptothecins is associated with the generation of abnormally high levels of double strand breaks in nascent DNA. Cancer Res. 53:2012-2019 (1993).
41. Smith, P. J., T. A. Makinson, and J. V. Watson. Enhanced sensitivity to camptothecin in ataxia telangiectasia cells and its relationship with the expression of DNA topoisomerase I. Int. J. Radiat. Biol. 55:217-231 (1989).
42. Jones, N. J., S. Ellard, R. Waters, and E. M. Parry. Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells. Carcinogenesis 14:2487-2494 (1993).
43. Zeng-Rong, N., J. Paterson, L. Alpert, M. -S. Tsao, J. Viallet, and M. A. Alaoui-Jamali. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res. 55:4760-4764 (1995).
44. Dabholkar, M., R. Parker, and E. Reed. Determinants of cisplatin sensitivity in non-malignant non-drug-selected human T cell lines. Mutat. Res. 274:45-46 (1992).
45. Chao, C., Y. Lee, P. Cheng, and S. Lin-Shao. Enhanced host cell reactivation of damaged plasmid DNA in HeLa cells resistant to cis-diammine-dichloroplatinum(II). Cancer Res. 51:601-605 (1991).